185 related articles for article (PubMed ID: 1649570)
21. Phenotypic characterization of quinolone-resistant mutants of Enterobacteriaceae selected from wild type, gyrA type and multiply-resistant (marA) type strains.
Piddock LJ; Hall MC; Walters RN
J Antimicrob Chemother; 1991 Aug; 28(2):185-98. PubMed ID: 1663926
[TBL] [Abstract][Full Text] [Related]
22. Spontaneous quinolone resistance in Serratia marcescens due to a mutation in gyrA.
Masecar BL; Robillard NJ
Antimicrob Agents Chemother; 1991 May; 35(5):898-902. PubMed ID: 1649573
[TBL] [Abstract][Full Text] [Related]
23. A novel, double mutation in DNA gyrase A of Escherichia coli conferring resistance to quinolone antibiotics.
Truong QC; Nguyen Van JC; Shlaes D; Gutmann L; Moreau NJ
Antimicrob Agents Chemother; 1997 Jan; 41(1):85-90. PubMed ID: 8980760
[TBL] [Abstract][Full Text] [Related]
24. Susceptibility of Campylobacter species to nalidixic acid, enoxacin, and other DNA gyrase inhibitors.
Taylor DE; Ng LK; Lior H
Antimicrob Agents Chemother; 1985 Nov; 28(5):708-10. PubMed ID: 3004325
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of clinical resistance to fluoroquinolones in Staphylococcus aureus.
Nakanishi N; Yoshida S; Wakebe H; Inoue M; Yamaguchi T; Mitsuhashi S
Antimicrob Agents Chemother; 1991 Dec; 35(12):2562-7. PubMed ID: 1667255
[TBL] [Abstract][Full Text] [Related]
26. DNA gyrase of Staphylococcus aureus and inhibitory effect of quinolones on its activity.
Takahata M; Nishino T
Antimicrob Agents Chemother; 1988 Aug; 32(8):1192-5. PubMed ID: 2847648
[TBL] [Abstract][Full Text] [Related]
27. Differing activities of quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus.
Maple PA; Hamilton-Miller JM; Brumfitt W
Antimicrob Agents Chemother; 1991 Feb; 35(2):345-50. PubMed ID: 1827242
[TBL] [Abstract][Full Text] [Related]
28. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Nishino Y; Ishihara S; Kawada Y
J Antimicrob Chemother; 1997 Oct; 40(4):543-9. PubMed ID: 9372424
[TBL] [Abstract][Full Text] [Related]
29. Development of resistance to quinolones in five patients with campylobacteriosis treated with norfloxacin or ciprofloxacin.
Adler-Mosca H; Lüthy-Hottenstein J; Martinetti Lucchini G; Burnens A; Altwegg M
Eur J Clin Microbiol Infect Dis; 1991 Nov; 10(11):953-7. PubMed ID: 1794366
[TBL] [Abstract][Full Text] [Related]
30. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy.
Aubert G; Pozzetto B; Dorche G
J Antimicrob Chemother; 1992 Mar; 29(3):307-12. PubMed ID: 1317371
[TBL] [Abstract][Full Text] [Related]
31. Dissociated resistance among fluoroquinolones.
Thomson KS; Sanders CC
Antimicrob Agents Chemother; 1994 Sep; 38(9):2095-100. PubMed ID: 7811025
[TBL] [Abstract][Full Text] [Related]
32. Sequence analysis, purification, and study of inhibition by 4-quinolones of the DNA gyrase from Mycobacterium smegmatis.
Revel-Viravau V; Truong QC; Moreau N; Jarlier V; Sougakoff W
Antimicrob Agents Chemother; 1996 Sep; 40(9):2054-61. PubMed ID: 8878580
[TBL] [Abstract][Full Text] [Related]
33. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.
Fournier B; Hooper DC
Antimicrob Agents Chemother; 1998 Jan; 42(1):121-8. PubMed ID: 9449271
[TBL] [Abstract][Full Text] [Related]
34. Frequency and expression of mutational resistance to the 4-quinolone antibacterials.
Smith JT
Scand J Infect Dis Suppl; 1986; 49():115-23. PubMed ID: 3547618
[TBL] [Abstract][Full Text] [Related]
35. In vitro activity of AT-4140 against quinolone- and methicillin-resistant Staphylococcus aureus.
Kojima T; Inoue M; Mitsuhashi S
Antimicrob Agents Chemother; 1990 Jun; 34(6):1123-7. PubMed ID: 2393270
[TBL] [Abstract][Full Text] [Related]
36. Studies on the emergence of resistance to lomefloxacin in vitro.
Kanematsu M; Greenwood D
Eur J Clin Microbiol Infect Dis; 1989 Aug; 8(8):741-5. PubMed ID: 2506046
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of quinolone resistance in a clinical isolate of Escherichia coli highly resistant to fluoroquinolones but susceptible to nalidixic acid.
Moniot-Ville N; Guibert J; Moreau N; Acar JF; Collatz E; Gutmann L
Antimicrob Agents Chemother; 1991 Mar; 35(3):519-23. PubMed ID: 2039202
[TBL] [Abstract][Full Text] [Related]
38. Antagonism between bactericidal activities of 4-quinolones and coumarins gives insight into 4-quinolone killing mechanisms.
Howard BM; Pinney RJ; Smith JT
Microbios; 1994; 77(311):121-31. PubMed ID: 8152392
[TBL] [Abstract][Full Text] [Related]
39. New Escherichia coli gyrA and gyrB mutations which have a graded effect on DNA supercoiling.
Aleixandre V; Urios A; Herrera G; Blanco M
Mol Gen Genet; 1989 Oct; 219(1-2):306-12. PubMed ID: 2559316
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of action of lomefloxacin.
Piddock LJ; Hall MC; Wise R
Antimicrob Agents Chemother; 1990 Jun; 34(6):1088-93. PubMed ID: 2168142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
